Connor, Clark & Lunn Investment Management (CC&L)
ANIP icon

Connor, Clark & Lunn Investment Management (CC&L)’s ANI Pharmaceuticals ANIP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,225
Closed -$325K – 1633
2026
Q1 		$325K Sell
4,225
-74,332
-95% -$5.8M ﹤0.01% 1404
2025
Q4 		$6.2M Sell
78,557
-50,132
-39% -$4.34M 0.02% 587
2025
Q3 		$11.8M Buy
128,689
+59,075
+85% +$4.82M 0.04% 373
2025
Q2 		$4.54M Buy
69,614
+22,864
+49% +$1.49M 0.02% 602
2025
Q1 		$3.13M Buy
46,750
+31,308
+203% +$1.87M 0.01% 612
2024
Q4 		$854K Buy
15,442
+1,972
+15% +$113K ﹤0.01% 990
2024
Q3 		$804K Buy
13,470
+6,728
+100% +$410K ﹤0.01% 950
2024
Q2 		$429K Sell
6,742
-8,560
-56% -$556K ﹤0.01% 1088
2024
Q1 		$1.06M Buy
15,302
+6,867
+81% +$415K ﹤0.01% 870
2023
Q4 		$465K Sell
8,435
-877
-9% -$48.3K ﹤0.01% 1059
2023
Q3 		$541K Buy
+9,312
New +$537K ﹤0.01% 993

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ANIP Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 4,225 shares — an estimated $325K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ANIP in Q3 2023 and held it in 11 quarters. The position peaked at $11.8M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 4,225 ANI Pharmaceuticals shares in Q2 2026, an estimated $325K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ANI Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s ANI Pharmaceuticals position peaked at $11.8M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.